HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NSAIDs Marketed In US Will Have Stronger Label Warning About Risks During Late Pregnancy

Executive Summary

In Drug Safety Communication, FDA says it is requiring labeling changes for Rx as well as OTC NSAIDs due to risk of rare but serious kidney problems in an unborn baby.

You may also be interested in...



CBD Firm Targeting Veterans, Military Takes Broadside On COVID Claims From US Agencies

FTDA and FTC warn Patriot Supreme about noncompliant claims on its website and social media pages promoting CBD to prevent or treat infections from the coronavirus. However, a release Patriot Supreme distributed in July promoting CBD as a COVID-19 remedy remains in online circulation.

US Firms’ Reducing Allergy Claims For Infant Nutritionals Scratch FDA's Enforcement Discretion

“To the extent these claims pertain to the ingestion of peanuts, they are not consistent with the claim in the [2017] Letter of Enforcement Discretion FDA issued in response to a petition for a qualified health claim for ground peanuts and reduced risk of developing peanut allergy,” state CFSAN officials.

Bloodroot, Zinc Make A Corrosive Mix In Homeopathic Topicals, US FDA Warns

Warnings state each’s firm products “are concerning from a public health perspective because they are labeled to contain the ingredients bloodroot (Sanguinaria canadensis) and zinc chloride … known corrosive agents.” The combination results in a corrosive topical agent capable of indiscriminately damaging healthy and diseased tissue alike.

Topics

UsernamePublicRestriction

Register

OM013057

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel